MOTS-c at Altitude: A Front Range Endurance Peptide Guide

The Leadville Starting Line

This is the Front Range endurance scene at the edge of what training can prepare a body for. Leadville. The Pikes Peak Ascent. The Bolder Boulder. Trail runners chasing Western States qualifiers in the Indian Peaks. Gravel riders putting in six-hour base rides up Magnolia Road and Lefthand Canyon. Cyclists training at 8,500 feet on the Peak to Peak Highway. The training is hard everywhere. At altitude, the recovery between sessions is what separates the athletes who progress from the ones who plateau in week three.

Altitude Is a Layer on Top of Training

Most endurance peptide content treats altitude as an afterthought. That framing misses what the body actually does up there. Altitude is not just "harder training." It is a separate physiological stress that runs concurrently with the training stress, and your recovery has to keep up with both at once.

The headline adaptation everyone talks about is erythropoiesis: the body responds to reduced arterial oxygen by ramping up red blood cell production, mediated by EPO (erythropoietin) released from the kidneys. This process takes one to four weeks depending on the altitude, the individual, and the existing baseline. It is the reason "live high, train low" works. It is also the part of altitude adaptation that no peptide accelerates. EPO itself is a prescription drug; supplemental MOTS-c, NAD+, CJC-1295/Ipamorelin do not move that needle.

What peptides can support is the layer underneath. The mitochondrial machinery that produces ATP from oxygen is working harder per molecule at altitude. The cortisol baseline shifts. Sleep quality degrades in the first week. Tissue repair runs slower when systemic recovery is competing with acclimatization for resources. That entire layer is where MOTS-c, NAD+, and CJC-1295/Ipamorelin actually do their work.

Days 1 to 3 at Altitude

The first 72 hours at altitude are the hardest. Arterial oxygen saturation drops from the 97-99% you carry at sea level to the high 80s or low 90s above 8,000 feet. Resting heart rate elevates by 10-20 beats per minute. Breathing rate increases. Sleep quality usually drops sharply, with frequent waking and a sense of restlessness through the first two or three nights. Some athletes get the classic AMS symptoms: headache, nausea, loss of appetite, fatigue out of proportion to effort.

This window is not where peptide therapy earns its keep. The most evidence-backed AMS prevention is gradual ascent (when feasible), hydration, and prescription acetazolamide (Diamox) under medical supervision for athletes with a history of AMS. NAD+ may support cellular energy through the adjustment, but framing it as an altitude-sickness drug overstates what the evidence shows. If you have a history of bad AMS, the conversation to have is with a physician about acetazolamide, not about peptide therapy.

For athletes arriving for an extended training block (a 2-4 week altitude camp, a race-week trip to Steamboat or Telluride, a Front Range relocation), the practical move during days 1-3 is to keep training easy, sleep as much as possible, hydrate aggressively, and let the cardiovascular system catch up. If NAD+ is part of your protocol, this is a reasonable window for it. Heavy intervals on day two are a waste at best.

Building Adaptation: MOTS-c at Altitude

MOTS-c (Mitochondrial-Derived Peptide) is the newest peptide in clinical use, discovered in 2015 by Changhan David Lee's lab at USC and published in Cell Metabolism. It was the first peptide ever found to be encoded by mitochondrial DNA rather than nuclear DNA, which is genuinely strange biology. Mitochondria, the cellular structures that produce ATP from oxygen, have their own small genome inherited maternally. MOTS-c is a 16-amino-acid peptide that comes from that genome.

In animal models, MOTS-c improves insulin sensitivity, increases fat oxidation, and acts as an exercise mimetic at the mitochondrial level. It is released by skeletal muscle during exercise itself, suggesting it is part of the body's own response to training stress. The published human data on supplemental MOTS-c is still early. There is no RCT showing it improves VO2 max in humans, and athletes who use it should not expect that. What they tend to report subjectively is improved aerobic feel on long zone 2 efforts (3+ hours), faster recovery between back-to-back long days, and a sense that the engine has more headroom.

For altitude athletes specifically, MOTS-c earns its keep through the mitochondrial-efficiency angle. At altitude, mitochondria are working harder per ATP produced because oxygen is scarcer. Supporting mitochondrial function during the adaptation window is theoretically aligned with what altitude training is asking the body to build anyway. Front Range athletes typically bring MOTS-c into the protocol 8-12 weeks before an A-race or before a multi-week altitude camp. The mechanism takes 3-6 weeks to start showing up subjectively, which is why timing matters.

Practical pattern: start MOTS-c at the beginning of base build, hold through build and peak, taper to maintenance in race week, pause for 2-3 weeks of post-event recovery, then back on for the next build. The receptor biology is not fully characterized in humans, and the consensus on cycling versus year-round dosing is based on common practice rather than head-to-head trial data.

NAD+ at Altitude

NAD+ (Nicotinamide Adenine Dinucleotide) is the coenzyme that every cell uses to convert food into ATP, and tissue NAD+ levels drop both with age and with chronic training load. Heavy training depletes the NAD+ pool faster than easy training does. At altitude, where the cellular machinery is already under more demand, the depletion accelerates further.

Injectable NAD+ bypasses the GI conversion limits that cap how much oral NMN or NR can actually raise tissue NAD+. For altitude athletes, the practical role is cellular-energy support during the adaptation window and through heavy training weeks. A common cadence is 2-3x weekly at maintenance dose, with a higher dose at the start of an altitude block and 24-48 hours after the biggest weekly ride or run.

NAD+ is also the one peptide in the altitude stack that is currently not on the WADA Prohibited List as of the 2026 update. That matters for athletes who compete in sanctioned events. Always verify against the current WADA list directly before any sanctioned competition, since the list updates annually.

CJC-1295/Ipamorelin for Masters Athletes

CJC-1295/Ipamorelin is a growth hormone-releasing peptide blend. CJC-1295 extends the half-life of the GHRH (growth hormone-releasing hormone) signal. Ipamorelin selectively stimulates the GH pulse without raising cortisol or prolactin, which is a cleaner profile than older GHRPs like GHRP-6.

The relevance for altitude athletes, especially masters athletes (40+), is overnight recovery. The largest natural GH pulse happens during deep (slow-wave) sleep, which is when most overnight tissue repair runs. At altitude, deep sleep is harder to come by, particularly in the first week. CJC-1295/Ipamorelin supports the GH pulse that would otherwise be degraded.

Common pattern: CJC/Ipa during the 8-12 week offseason build for masters athletes who want to retain lean mass through winter, plus a maintenance dose during long altitude training camps. Taper 7-10 days before any A-race to avoid water retention on race day. This is the optional peptide in the altitude stack; MOTS-c and NAD+ are the core. CJC/Ipa is for the athlete who wants the overnight-recovery layer on top.

Race Day at Altitude

Race day is execution. The peptide protocol is not what gets you to the finish line. Training and altitude exposure are. The peptide protocol exists to make sure you arrive at the start line healthy and recover well enough to do this again.

Race-week peptide pattern: MOTS-c tapers to a maintenance dose (the mitochondrial work is done by this point). NAD+ continues at maintenance. CJC/Ipa pauses 7-10 days before to avoid race-morning water retention. BPC-157 stays in reserve in case of pre-race tendon or hip-flexor tweaks.

Do not dose anything new on race morning. Whatever your pre-race ritual is, that is the ritual. BPC-157 is not a painkiller; do not dose it expecting it to mask discomfort so you can push through. The repair signaling does not work on that timescale.

The WADA Reality

For recreational endurance athletes who do not compete in sanctioned categories (most Leadville finishers, most Front Range trail runners, most gravel cyclists racing non-sanctioned events), WADA status is informational rather than restrictive. For sanctioned competitors, it is the deciding factor. The practical implication: if you race a USAT-sanctioned triathlon next month, the peptides in this guide are not part of your stack right now.

What Altitude Peptides Will Not Do

Peptide therapy at altitude gets confused with several things it is not. Four honest distinctions.

Not an EPO substitute. Erythropoiesis is the red blood cell response that defines altitude adaptation. EPO (erythropoietin) is a prescription drug. None of the peptides in this guide raise red blood cell mass, hematocrit, or hemoglobin. If you are looking for "natural EPO" you will not find it here. Spend more time at altitude.

Not an altitude-sickness prevention. Acute mountain sickness has documented preventive strategies: gradual ascent, hydration, and prescription acetazolamide for athletes with a history of AMS. Peptide therapy is not in that toolkit. NAD+ may support cellular energy through the adjustment; it is not a substitute for the actual AMS prevention conversation with a physician.

Not a VO2 max booster. Published human data on supplemental MOTS-c does not show a direct increase in VO2 max. The athletes who use it report improved long-duration aerobic feel and faster between-session recovery, which is real but is not the same as a maximal-oxygen-uptake upgrade. Be honest with yourself about what you are buying.

Not a substitute for the work. No peptide replaces the actual zone 2 volume, the long days in the saddle, the specific climbing repeats, the altitude exposure that builds the adaptations. Peptide therapy is a recovery and adaptation layer. If the training is not there, the peptides are not what is missing.

A Few Practical Questions